Lodo Therapeutics utilizes advanced AI models and lab automation to streamline drug discovery and development processes, providing access to high-quality datasets for researchers. The company addresses the challenges of lengthy R&D timelines and high costs in bringing new therapeutics to market.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug discovery and development processes are often slow, expensive, and yield limited high-quality datasets for researchers, hindering the efficient creation of new therapeutics. Lengthy R&D timelines and high costs present significant challenges in bringing innovative treatments to market.
Solution
Ginkgo Bioworks offers a platform that combines automated labs, artificial intelligence (AI) models, and biological expertise to accelerate research and development (R&D) across multiple industries. The company provides access to large, high-quality datasets and AI tools, enabling partners to streamline their R&D processes. Ginkgo's platform supports custom R&D projects, packaged services, and individual R&D tools, allowing partners to choose the solutions that best fit their needs. By leveraging Ginkgo's infrastructure, companies can overcome R&D challenges and speed up the development of new products.
Target Audience
Ginkgo Bioworks serves organizations across various sectors, including agriculture, biopharma, biosecurity, government, and industrial biotech, seeking to accelerate their R&D efforts.
Features
- Large, high-quality datasets for various applications
- AI models to accelerate data analysis and discovery
- Automated labs to streamline experimental workflows
- Custom R&D project support tailored to specific needs
- Packaged services for standardized research tasks
- R&D tools accessible via the Ginkgo Datapoints, Ginkgo AI, and Ginkgo Automation platforms
- Solutions for agriculture, biopharma, biosecurity, government, and industrial biotech sectors